100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
693793-53-2Atorvastatin Related Compound C (Ca Salt)
● In Stock
| Catalogue No.: | VL10005 |
|---|---|
| CAS No.: | 693793-53-2 |
| Mol. Formula: | C66H66CaF4N4O10 |
| Mol. Weight: | 1191.34 g/mol |
Additional information on CAS 693793-53-2
Parent drug
AtorvastatinIUPAC Name
(3R,5R)-7-[2,3-bis(4-fIuorophenyI)-4-(phenyIcarbamoyI)-5-(propan-2-yI)-1 H-pyrroI-1-yI]-3,5-dihydroxyheptanoic acid Calcium Salt(1:2)Pharmacopeial Synonyms
Atorvastatin Related compound C Calcium salt; Atorvastatin Difluoro Impurity Calcium salt; Fluoroatorvastatin Calcium saltSynonyms
N/ASmiles
[Ca+2].CC(C)c1c(C(=O)Nc2ccccc2)c(c3ccc(F)cc3)c(c4ccc(F)cc4)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c5c(C(=O)Nc6ccccc6)c(c7ccc(F)cc7)c(c8ccc(F)cc8)n5CC[C@@H](O)C[C@@H](O)CC(=O)[O-]InChI
InChI=1S/2C33H34F2N2O5.Ca/c2*1-20(2)31-30(33(42)36-25-6-4-3-5-7-25)29(21-8-12-23(34)13-9-21)32(22-10-14-24(35)15-11-22)37(31)17-16-26(38)18-27(39)19-28(40)41;/h2*3-15,20,26-27,38-39H,16-19H2,1-2H3,(H,36,42)(H,40,41);/q;;+2/p-2/t2*26-,27-;/m11./s1Description
Atorvastatin EP Impurity C, also designated Atorvastatin Related Compound C, Atorvastatin Difluoro Impurity, or Fluoroatorvastatin, is a fluorinated atorvastatin analogue present as the calcium salt (CAS 693793-53-2). With molecular formula C66H66CaF4N4O10 and molecular weight 1191.34 g/mol, it reflects halogen introduction at the aryl substitution pattern of the statin scaffold rather than a simple degradant. Such species typically arise from synthetic impurity carryover or misincorporation during late-stage coupling and require orthogonal characterization by LC-MS/MS, high-resolution MS, and ideally 19F NMR with LC-UV profiling for low-level quantification under impurity control frameworks.References
Agrawal, Deepak, et al. ‘To Study the Effect of High Dose Atorvastatin 40 Mg versus 80 Mg in Patients with Dyslipidemia.’ Indian Heart Journal, vol. 70, Dec. 2018, pp. S8–12, https://doi.org/10.1016/j.ihj.2018.01.034.Request a Quote
« * » indique les champs nécessaires
Other products related to Atorvastatin impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
